The ITRGM signature includes GBP5, HLA-DPB1, XBP1, CD40, CXCL10, and TNFSF13B, each playing pivotal roles in the immune response and tumor microenvironment of melanoma. This evidence concerns the gene HLA-DPB1 and melanoma.